Skip to main content
Top
Published in: Rheumatology International 9/2011

01-09-2011 | Original Article

Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus

Authors: Hyoun-Ah Kim, Jun-Mo Sung, Ja-Young Jeon, Jeong-Moon Yoon, Chang-Hee Suh

Published in: Rheumatology International | Issue 9/2011

Login to get access

Abstract

Vitamin D is a pleiotrophic hormone with immunoregulatory properties. Low levels of vitamin D have been discovered in various autoimmune diseases. Here, we investigated serum vitamin D levels in Koreans with systemic lupus erythematosus (SLE) and examined whether levels correlate with disease activity of SLE. Blood samples were prospectively collected from patients with SLE (n = 104) and normal controls (NC, n = 49) during the spring from March to May 2008. The level of serum 25-hydroxyvitamin D (25(OH)D3) was measured by radioimmunoassay. The serum 25(OH)D3 levels of patients with SLE (42.49 ± 15.08 ng/ml) were significantly lower than NC (52.72 ± 15.19 ng/ml, P < 0.001). Additionally, 17 patients with SLE (16.3%) had vitamin D insufficiency, while two NC had vitamin D insufficiency (4.1%). The risk of vitamin D insufficiency was 4.6-fold increased in SLE (P = 0.032). The serum 25(OH)D3 levels, adjusted with BMI, were positively correlated only with hemoglobin (β = 0.256, P = 0.018) and serum complement 3 (β = 0.365, P = 0.002). Serum vitamin D levels were lower, and vitamin D insufficiency was more common in Korean patients with SLE, however, our study demonstrated that vitamin D levels might not be a good marker of disease activity.
Literature
2.
go back to reference van Etten E, Mathieu C (2005) Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101PubMedCrossRef van Etten E, Mathieu C (2005) Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101PubMedCrossRef
3.
go back to reference Bhalla AK, Amento EP, Serog B et al (1984) 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 133:1748–1754PubMed Bhalla AK, Amento EP, Serog B et al (1984) 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 133:1748–1754PubMed
4.
5.
go back to reference Mattner F, Smiroldo S, Galbiati F et al (2000) Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25-dihydroxyvitamin D(3). Eur J Immunol 30:498–508PubMedCrossRef Mattner F, Smiroldo S, Galbiati F et al (2000) Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25-dihydroxyvitamin D(3). Eur J Immunol 30:498–508PubMedCrossRef
6.
go back to reference Linker-Israeli M, Elstner E, Klinenberg JR et al (2001) Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol 99:82–93PubMedCrossRef Linker-Israeli M, Elstner E, Klinenberg JR et al (2001) Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol 99:82–93PubMedCrossRef
7.
go back to reference Holick MF (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362–371PubMed Holick MF (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362–371PubMed
8.
go back to reference Cantorna MT, Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 229:1136–1142 Cantorna MT, Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 229:1136–1142
9.
go back to reference Bultink IE, Lems WF, Kostense PJ et al (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52:2044–2050PubMedCrossRef Bultink IE, Lems WF, Kostense PJ et al (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52:2044–2050PubMedCrossRef
10.
go back to reference Muller K, Kriegbaum NJ, Baslund B et al (1995) Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 14:397–400PubMedCrossRef Muller K, Kriegbaum NJ, Baslund B et al (1995) Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 14:397–400PubMedCrossRef
11.
go back to reference Huisman AM, White KP, Algra A et al (2001) Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 28:2535–2539PubMed Huisman AM, White KP, Algra A et al (2001) Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 28:2535–2539PubMed
12.
go back to reference Kamen DL, Cooper GS, Bouali H et al (2006) Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 5:114–117PubMedCrossRef Kamen DL, Cooper GS, Bouali H et al (2006) Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 5:114–117PubMedCrossRef
14.
go back to reference Chen S, Sims GP, Chen XX et al (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647PubMed Chen S, Sims GP, Chen XX et al (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647PubMed
15.
go back to reference Orbach H, Zandman-Goddard G, Amital H et al (2007) Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci 1109:385–400PubMedCrossRef Orbach H, Zandman-Goddard G, Amital H et al (2007) Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci 1109:385–400PubMedCrossRef
16.
go back to reference Ruiz-Irastorza G, Egurbide MV, Olivares N et al (2008) Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2047:920–923CrossRef Ruiz-Irastorza G, Egurbide MV, Olivares N et al (2008) Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2047:920–923CrossRef
17.
go back to reference Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
18.
go back to reference Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI.A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI.A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef
19.
go back to reference Gladman DD, Goldsmith CH, Urowitz MB et al (2000) The systemic lupus international collaborating clinics/American college of rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 27:373–376PubMed Gladman DD, Goldsmith CH, Urowitz MB et al (2000) The systemic lupus international collaborating clinics/American college of rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 27:373–376PubMed
20.
go back to reference Kim HA, Jeon JY, Choi GS et al (2008) The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol 128:277–283PubMedCrossRef Kim HA, Jeon JY, Choi GS et al (2008) The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol 128:277–283PubMedCrossRef
21.
go back to reference O’Regan S, Chesney RW, Hamstra A et al (1979) Reduced serum 1, 25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand 68:109–111PubMedCrossRef O’Regan S, Chesney RW, Hamstra A et al (1979) Reduced serum 1, 25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand 68:109–111PubMedCrossRef
22.
go back to reference Borba VZ, Vieira JG, Kasamatsu T et al (2009) Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 20:427–433PubMedCrossRef Borba VZ, Vieira JG, Kasamatsu T et al (2009) Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 20:427–433PubMedCrossRef
23.
go back to reference Thudi A, Yin S, Wandstrat AE et al (2008) Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci 335:99–104PubMedCrossRef Thudi A, Yin S, Wandstrat AE et al (2008) Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci 335:99–104PubMedCrossRef
24.
go back to reference Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67:373–378PubMedCrossRef Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67:373–378PubMedCrossRef
25.
go back to reference Klein RG, Arnaud SB, Gallagher JC et al (1977) Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 60:253–259PubMedCrossRef Klein RG, Arnaud SB, Gallagher JC et al (1977) Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 60:253–259PubMedCrossRef
26.
go back to reference Hahn TJ, Halstead LR, Haddad JG Jr (1977) Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med 90:399–404PubMed Hahn TJ, Halstead LR, Haddad JG Jr (1977) Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med 90:399–404PubMed
27.
go back to reference O’Leary TJ, Jones G, Yip A (1986) The effects of chloroquine on serum 1, 25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 315:727–730PubMedCrossRef O’Leary TJ, Jones G, Yip A (1986) The effects of chloroquine on serum 1, 25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 315:727–730PubMedCrossRef
28.
go back to reference Zold E, Szodoray P, Gaal J et al (2008) Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 10:R123PubMedCrossRef Zold E, Szodoray P, Gaal J et al (2008) Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 10:R123PubMedCrossRef
29.
go back to reference Costenbader KH, Feskanich D, Holmes M et al (2008) Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 67:530–535PubMedCrossRef Costenbader KH, Feskanich D, Holmes M et al (2008) Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 67:530–535PubMedCrossRef
Metadata
Title
Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus
Authors
Hyoun-Ah Kim
Jun-Mo Sung
Ja-Young Jeon
Jeong-Moon Yoon
Chang-Hee Suh
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 9/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1442-1

Other articles of this Issue 9/2011

Rheumatology International 9/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.